Full Breakdown
Eli Lilly's Orforglipron Shows Promising Results in Phase 3 Trials for Type 2 Diabetes
10/16/2025, 1:31:58 AM
Overview of the Trials
Eli Lilly and Company has announced positive topline results from two Phase 3 clinical trials, ACHIEVE-2 and ACHIEVE-5, evaluating its investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron, for the treatment of type 2 diabetes. The ACHIEVE-2 trial compared orforglipron against dapagliflozin, an SGLT-2 inhibitor, while ACHIEVE-5 assessed orforglipron against a placebo in patients inadequately controlled on insulin glargine. Both trials met their primary endpoints, demonstrating significant reductions in A1C levels, a key measure of blood sugar control.
Key Findings
In the ACHIEVE-2 trial, which involved 962 participants, orforglipron lowered A1C levels by up to 1.7% compared to a 0.8% reduction with dapagliflozin. The ACHIEVE-5 trial, with 546 participants, showed an additional A1C reduction of 2.1% when orforglipron was used alongside insulin glargine. All doses of orforglipron (3 mg, 12 mg, and 36 mg) achieved statistical significance with p<0.001 for both trials. Participants also experienced weight loss and improvements in cardiovascular risk factors.
Safety and Tolerability
The safety profile of orforglipron was consistent with previous studies, with gastrointestinal issues being the most common adverse events, generally mild to moderate in severity. No hepatic safety signals were observed, and treatment discontinuation rates were in line with prior research.
Regulatory Path and Future Trials
Eli Lilly plans to submit orforglipron for regulatory approval for type 2 diabetes in 2026, with a submission for obesity treatment expected by the end of 2025. The final global registration trial, ACHIEVE-4, is anticipated to yield results in the first quarter of 2026. The ACHIEVE program has enrolled over 6,000 participants across five global trials.
Criticism and Market Context
Despite the promising results, some analysts have expressed skepticism regarding the need for higher doses of orforglipron, as A1C reductions were not consistently greater at the highest dose compared to the middle dose. Additionally, while Lilly aims to compete with Novo Nordisk in the oral GLP-1 market, concerns remain about the overall weight loss efficacy of orforglipron compared to existing treatments.
Official Statements
Jeff Emmick, M.D., Ph.D., senior vice president of product development at Lilly, stated, “Orforglipron has now demonstrated superiority over two active comparators in clinical trials for type 2 diabetes... Together, these results reinforce orforglipron's potential to become a new standard of care for people living with type 2 diabetes.”
Conclusion
The results from the ACHIEVE-2 and ACHIEVE-5 trials position orforglipron as a potentially significant advancement in the treatment of type 2 diabetes, with the possibility of becoming a foundational therapy. As Eli Lilly moves forward with regulatory submissions and additional trials, the drug's market impact will depend on its acceptance among healthcare providers and patients alike.
